Short Interest in Zealand Pharma A/S (OTCMKTS:ZLDPF) Expands By 39.7%

Zealand Pharma A/S (OTCMKTS:ZLDPF) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 1,166,300 shares, a growth of 39.7% from the December 15th total of 835,100 shares. Based on an average trading volume of 2,100 shares, the short-interest ratio is presently 555.4 days.

Zealand Pharma A/S Stock Performance

Shares of ZLDPF opened at $95.29 on Thursday. The company has a debt-to-equity ratio of 0.03, a current ratio of 35.49 and a quick ratio of 35.49. Zealand Pharma A/S has a one year low of $64.10 and a one year high of $141.74. The firm has a market capitalization of $4.91 billion, a P/E ratio of -39.21 and a beta of 0.89. The business has a fifty day moving average of $104.95 and a 200 day moving average of $119.05.

Wall Street Analysts Forecast Growth

Separately, JPMorgan Chase & Co. initiated coverage on Zealand Pharma A/S in a report on Friday, November 8th. They issued an “overweight” rating for the company.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.